V
83.98
-0.83 (-0.98%)
| Penutupan Terdahulu | 84.81 |
| Buka | 84.50 |
| Jumlah Dagangan | 1,316,240 |
| Purata Dagangan (3B) | 1,405,753 |
| Modal Pasaran | 7,136,527,872 |
| Harga / Jualan (P/S) | 64.24 |
| Harga / Buku (P/B) | 34.64 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2025 - 11 Aug 2025 |
| Margin Keuntungan | -138.31% |
| Margin Operasi (TTM) | -13.53% |
| EPS Cair (TTM) | -2.00 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 107.63% |
| Nisbah Semasa (MRQ) | 8.86 |
| Aliran Tunai Operasi (OCF TTM) | -120.15 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -69.15 M |
| Pulangan Atas Aset (ROA TTM) | -20.64% |
| Pulangan Atas Ekuiti (ROE TTM) | -72.61% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Verona Pharma plc | Menaik | Menaik |
AISkor Stockmoo
1.5
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 4.0 |
| Purata | 1.50 |
|
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 10.88% |
| % Dimiliki oleh Institusi | 90.76% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Summit Partners Public Asset Management, Llc | 31 Mar 2025 | 2,323,115 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 110.00 (Jefferies, 30.98%) | Beli |
| Median | 103.50 (23.24%) | |
| Rendah | 90.00 (HC Wainwright & Co., 7.17%) | Beli |
| Purata | 101.75 (21.16%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 84.07 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Cantor Fitzgerald | 11 Jun 2025 | 100.00 (19.08%) | Beli | 90.05 |
| Jefferies | 11 Jun 2025 | 110.00 (30.98%) | Beli | 90.05 |
| HC Wainwright & Co. | 02 Jun 2025 | 90.00 (7.17%) | Beli | 84.10 |
| 30 Apr 2025 | 85.00 (1.21%) | Beli | 72.07 | |
| Wells Fargo | 30 Apr 2025 | 107.00 (27.41%) | Beli | 72.07 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| HAHN MARK W | - | 90.05 | -400,000 | -36,020,000 |
| ZACCARDELLI DAVID | - | 90.05 | -400,000 | -36,020,000 |
| Jumlah Keseluruhan Kuantiti Bersih | -800,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -72,040,000 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 90.05 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| ZACCARDELLI DAVID | Pegawai | 11 Jun 2025 | Jual automatik (-) | 400,000 | 90.05 | 36,020,000 |
| HAHN MARK W | Pegawai | 11 Jun 2025 | Jual automatik (-) | 400,000 | 90.05 | 36,020,000 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 21 May 2025 | Pengumuman | Verona Pharma Announces June 2025 Investor Conference Participation |
| 06 May 2025 | Pengumuman | Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025 |
| 29 Apr 2025 | Pengumuman | Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update |
| 16 Apr 2025 | Pengumuman | Ritedose Adds Seventh Syntegon Packaging Line to Expand Single Vial Packaging Capabilities, Support Production of new COPD Drug Ohtuvayre |
| 15 Apr 2025 | Pengumuman | Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update |
| 28 Mar 2025 | Pengumuman | Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |